Form 13-F position report

Y-MABS THERAPEUTICS INC

Reported by STATE STREET CORPORATION

YMAB CUSIP 984241109 Manager CIK 0000093751

Reported 780,145 shares, down 8,876 (1.1%) from the prior quarter.

Reported value 0.7%; share count -1.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 780,145 Quarter-end amount reported
Reported value $3,518,454 Fair value at quarter end
Consecutive quarters held 27 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 23613000
2022-03-31 27428000
2022-06-30 26374000
2022-09-30 27674000
2022-12-31 4060897
2023-03-31 3821778
2023-06-30 5055882
2023-09-30 4038984
2023-12-31 5193648
2024-03-31 12212447
2024-06-30 9719713
2024-09-30 15908620
2024-12-31 10291822
2025-03-31 3495363
2025-06-30 3518454
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for Y-MABS THERAPEUTICS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -780,145 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 780,145 -8,876 (-1.1%) < 0.01% $3,518,454 2025-08-14
Q1 2025 Reduced 789,021 -525,388 (-40.0%) < 0.01% $3,495,363 2025-05-15
Q4 2024 Added 1,314,409 +104,628 (8.6%) < 0.01% $10,291,822 2025-02-14
Q3 2024 Added 1,209,781 +405,169 (50.4%) < 0.01% $15,908,620 2024-11-14
Q2 2024 Added 804,612 +53,539 (7.1%) < 0.01% $9,719,713 2024-08-14
Q1 2024 Reduced 751,073 -10,459 (-1.4%) < 0.01% $12,212,447 2024-05-15
Q4 2023 Added 761,532 +20,434 (2.8%) < 0.01% $5,193,648 2024-02-14
Q3 2023 Reduced 741,098 -3,509 (-0.5%) < 0.01% $4,038,984 2023-11-14
Q2 2023 Reduced 744,607 -18,223 (-2.4%) < 0.01% $5,055,882 2023-08-14
Q1 2023 Reduced 762,830 -69,321 (-8.3%) < 0.01% $3,821,778 2023-05-15
Q4 2022 Reduced 832,151 -1,086,988 (-56.6%) < 0.01% $4,060,897 2023-02-14
Q3 2022 Added 1,919,139 +175,997 (10.1%) < 0.01% $27,674,000 2022-11-15
Q2 2022 Reduced 1,743,142 -565,640 (-24.5%) < 0.01% $26,374,000 2022-08-15
Q1 2022 Added 2,308,782 +852,112 (58.5%) < 0.01% $27,428,000 2022-05-16
Q4 2021 Added 1,456,670 +124,727 (9.4%) < 0.01% $23,613,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

115 managers reported Y-MABS THERAPEUTICS INC for Q2 2025.

Managers reporting Y-MABS THERAPEUTICS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Paradigm Biocapital Advisors LP Unchanged 4,236,346 0 0.82% $19,105,920 6 qtrs
ACORN CAPITAL ADVISORS LLC Added 3,418,995 +183,608 10.09% $15,419,668 3 qtrs
BlackRock Inc Reduced 2,748,077 -153,948 < 0.01% $12,393,829 4 qtrs
Caligan Partners LP Unchanged 2,342,609 0 2.03% $10,565,167 8 qtrs
Sofinnova Investments Inc Unchanged 2,194,278 0 0.61% $9,896,194 28 qtrs
VANGUARD GROUP INC Reduced 1,943,285 -3,224 < 0.01% $8,764,215 28 qtrs
Polar Capital Holdings Plc Reduced 1,789,800 -41,200 0.04% $8,071,998 19 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 848,461 -1,039 < 0.01% $3,827,252 27 qtrs
STATE STREET CORPORATION This report Reduced 780,145 -8,876 < 0.01% $3,518,454 27 qtrs
BOOTHBAY FUND MANAGEMENT LLC Unchanged 693,693 0 0.06% $3,128,555 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
740,122
Shared
0
None
40,023

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.